• Product NameLithium citrate tribasic tetrahydrate
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityLithium Citrate is the active component of Lithium which is a drug used in treatment of psychiatric disease. Lithium Citrate has shown the effects on metabolic and signaling pathways in the brain based on the specific clinical condition and disease model. Lithium Citrate has been reported to use as a mood stabilizer when treating bipolar mood disorders (BD) and reduce the risk of self-harm in BD patient. In addition, Lithium Citrate has been found to be the choice drug in treatment of acute manic episodes. Moreover, Lithium Citrate has been revealed to dissolve uric acid crystals in urine obtained from patients with gout. Besides, Lithium Citrate has been exhibited to have some dose-dependent side-effects. The most of the side-effects of Lithium Citrate is the tendency to inhibit the prostatic acid phosphatase enzyme (PAP), which leading to the accumulation of PAP
• Target NameDehydrogenase inhibitor; GluR potentiator; GSK-3 inhibitor
• CAS No. 6080-58-6
• Calculated MW 281.98
• Formulation C6H13Li3O11
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Other
  SMILES:[Li].[Li].[Li].O.O.O.O.OC(=O)CC(O)(CC(O)=O)C(O)=O
  Pathways:PI3K/Akt/mTOR signaling; Metabolism; Neuroscience; Stem Cells
  Receptor:IMPDH; mGluR3; GSK-3β
  Boling pt:309.6C
  Melting pt:112C
  Solubility:Soluble in DMSO
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Oruch R, et al. Eur J Pharmacol. 2014 Jun 30. pii: S0014-2999(14)00493-2

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting